Antibody-Drug Conjugates: Cancer Therapies to Watch
There are up to 80 ADCs in clinical development with close to 600 ongoing trials.
Kidney Cancer
Can Advocacy Groups Provide Useful Patient-Centered Data?
A survey presented during ASCO20 found that patients who considered themselves adequately informed felt “in control” most days.
Positive vs Negative Lymph Nodes Portend Worse Prognosis in Stage 3 RCC
In a study involving stage 3 RCC patients, those with positive lymph nodes had markedly inferior 5-year survival compared with those with lymph-node negative disease and 5-year survival similar to those with stage 4 RCC.
Antitumor Activity Reported With Lenvatinib/Pembrolizumab in Metastatic RCC After Disease Progression on ICI Therapy
Lenvatinib plus pembrolizumab resulted in antitumor activity in patients with metastatic clear cell RCC that progressed during or after treatment with an immune checkpoint inhibitor, according to phase 2 results.
Phase 3 PROSPER RCC Trial to Evaluate Neoadjuvant/Adjuvant Immunotherapy in Nonmetastatic RCC
The phase 3 PROSPER RCC trial will evaluate neoadjuvant with adjuvant nivolumab among patients with nonmetastatic RCC compared with surgery and standard-of-care surveillance.
Tivozanib Superior to Sorafenib in Heavily Pretreated Renal Cell Carcinoma
Tivozanib resulted in superior PFS compared with sorafenib among patients with RCC that progressed on 2 or 3 prior systemic regimens, including another VEGF inhibitor, according to the final analysis of the TIVO-3 trial.
Response-Based Addition of Ipilimumab to Nivolumab Not Effective in RCC
The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in few responses among patients who did not achieve a response with nivolumab alone, according to results of a phase 2 trial.
HIF-2α Inhibitor Demonstrates Promising Activity Against VHL-Associated RCC
A HIF-2α inhibitor demonstrated antitumor activity against VHL-associated clear cell RCC and other associated tumors, according to interim results of a phase 2 study.
Nivolumab Plus Ipilimumab Demonstrated Promising Activity in Previously ICI-Treated RCC
Preliminary phase 2 data suggest that nivolumab plus ipilimumab was efficacious in advanced RCC that previously progressed with immune checkpoint inhibitor therapy.
Pembrolizumab-Axitinib Continued to Offer Durable Benefits in Advanced RCC
Updated findings from KEYNOTE-426 showed that frontline pembrolizumab-axitinib continued to be associated with improved PFS and OS compared with sunitinib in advanced RCC.
-
Loading...
-
Loading...
